<DOC>
	<DOC>NCT01026233</DOC>
	<brief_summary>The purpose of this study is to evaluate cardiac safety of brentuximab vedotin (SGN-35) in patients with CD30-positive cancers. The study will assess electrical activity of the heart before and after brentuximab vedotin administration. Patients who have stable or improving disease may receive up to 1 year of brentuximab vedotin treatment.</brief_summary>
	<brief_title>Cardiac Safety Study of Brentuximab Vedotin (SGN-35)</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Relapsed or refractory CD30positive malignancy Adequate organ function ECOG performance status &lt;2 Cardiac abnormalities (abnormal rhythm, history of significant cardiac event) Current diagnosis of primary cutaneous ALCL Acute or chronic graftversushost disease Prior hematopoietic stem cell transplant within specified timeframe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antibodies, Monoclonal</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antigens, CD30</keyword>
	<keyword>Disease, Hodgkin</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>monomethylauristatin E</keyword>
	<keyword>Lymphoma, Large-Cell, Anaplastic</keyword>
</DOC>